Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
暂无分享,去创建一个
Y. Tomino | T. Gohda | S. Horikoshi | M. Tanimoto | Takamichi Ito | Shinji Hagiwara | Maki Murakoshi | T. Aoki | M. Matsumoto | S. Kaneko | Kaori Yamada | Tatsuya Aoki
[1] Ann Marie Schmidt,et al. Advanced glycation end products: sparking the development of diabetic vascular injury. , 2006, Circulation.
[2] Y. Tomino,et al. Glomerular changes in the KK‐Ay/Ta mouse: A possible model for human type 2 diabetic nephropathy , 2006, Nephrology.
[3] M. Nangaku,et al. Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. , 2005, Kidney international.
[4] Yusuke Suzuki,et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] R. Bucala,et al. AGEs activate mesangial TGF-b –Smad signaling via an angiotensin II type I receptor interaction , 2010 .
[6] Y. Tomino,et al. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. , 2004, Metabolism: clinical and experimental.
[7] S. Levine,et al. Pyridoxine (vitamin B6) neurotoxicity: enhancement by protein‐deficient diet , 2004, Journal of applied toxicology : JAT.
[8] Sushil K. Jain,et al. Effect of vitamin B6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H2O2-treated U937 monocytes. , 2004, Free radical biology & medicine.
[9] E. Van Obberghen,et al. Human Glycated Albumin Affects Glucose Metabolism in L6 Skeletal Muscle Cells by Impairing Insulin-induced Insulin Receptor Substrate (IRS) Signaling through a Protein Kinase Cα-mediated Mechanism* , 2003, Journal of Biological Chemistry.
[10] T. Metz,et al. Pyridoxamine Traps Intermediates in Lipid Peroxidation Reactions in Vivo , 2003, Journal of Biological Chemistry.
[11] J. Baynes,et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. , 2003, Kidney international.
[12] S. Horiuchi,et al. CD36‐mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3‐L1 and human subcutaneous adipocytes , 2003, FEBS letters.
[13] S. Levine,et al. Pyridoxine (vitamin B6) toxicity: enhancement by uremia in rats. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[14] S. Horiuchi,et al. Peroxynitrite induces formation of N( epsilon )-(carboxymethyl) lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose: novel pathways for protein modification by peroxynitrite. , 2002, Diabetes.
[15] E. Fisher,et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. , 2002, Diabetes.
[16] Z. Makita,et al. Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[17] N. Ruderman,et al. Hyperglycemia and Insulin Resistance: Possible Mechanisms , 2002, Annals of the New York Academy of Sciences.
[18] R. Nagaraj,et al. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. , 2002, Archives of biochemistry and biophysics.
[19] K. Oguchi,et al. Diabetic nephropathy in KK and KK-Ay mice. , 2002, Experimental animals.
[20] M. Steffes,et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.
[21] T. Metz,et al. A Post-Amadori Inhibitor Pyridoxamine Also Inhibits Chemical Modification of Proteins by Scavenging Carbonyl Intermediates of Carbohydrate and Lipid Degradation* , 2002, The Journal of Biological Chemistry.
[22] Maristela L Onozato,et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. , 2002, Kidney international.
[23] A. Schmidt,et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.
[24] S. Jain,et al. Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. , 2001, Free radical biology & medicine.
[25] A. Barden,et al. Advanced Glycation End Products: A Review , 2013 .
[26] K. Kannan,et al. Oxidative stress and apoptosis. , 2000, Pathophysiology : the official journal of the International Society for Pathophysiology.
[27] A. Jenkins,et al. Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions , 2000, The Journal of Biological Chemistry.
[28] B. Jortner. Mechanisms of Toxic Injury in the Peripheral Nervous System: Neuropathologic Considerations , 2000, Toxicologic pathology.
[29] R. Khalifah,et al. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. , 1999, Biochemical and biophysical research communications.
[30] Z. Makita,et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 , 1999, Diabetologia.
[31] D. B. Mccormick,et al. Update on interconversions of vitamin B-6 with its coenzyme. , 1999, The Journal of nutrition.
[32] Alan W. Stitt. Advanced Glycation Endproducts , 1999 .
[33] J. Baynes,et al. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.
[34] R. Ziegler,et al. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.
[35] V. Monnier,et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. , 1997, The Journal of clinical investigation.
[36] N. Hotta,et al. Effects of Glycemic Control on Plasma 3-Deoxyglucosone Levels in NIDDM Patients , 1997, Diabetes Care.
[37] S. I. Kim,et al. Pathogenic role of advanced glycosylation end products in diabetic nephropathy. , 1997, Kidney international. Supplement.
[38] Z. Makita,et al. Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation , 1997, Diabetes.
[39] A. Booth,et al. In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs) , 1997, The Journal of Biological Chemistry.
[40] J. Wautier,et al. Advanced glycation end products, oxidant stress and vascular lesions , 1997, European journal of clinical investigation.
[41] J. Mott,et al. Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies. , 1996, Biochemistry.
[42] F. Ziyadeh,et al. Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. , 1996, Journal of the American Society of Nephrology : JASN.
[43] A. Cerami,et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.
[44] M. Nishimura. Breeding of mice strains for diabetes mellitus , 1969 .